{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = 2-(3-Methoxyphenyl)-2-(methylamino)cyclohexanone
| image = Methoxmetamine.png
| width = 150

<!--Clinical data-->
| tradename = 
| legal_CA = Schedule I
| legal_UK = Class B

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 1781829-56-8
| CAS_supplemental =
| ATC_prefix =
| PubChem = 117067863

|  ChemSpiderID = 58939253

<!--Chemical data-->
| C=14 | H=19 | N=1 | O=2
| smiles = COC1=CC=CC(=C1)C2(CCCCC2=O)NC
| StdInChI = 1S/C14H19NO2/c1-15-14(9-4-3-8-13(14)16)11-6-5-7-12(10-11)17-2/h5-7,10,15H,3-4,8-9H2,1-2H3
| StdInChIKey = ZGQWDAOLJNAADS-UHFFFAOYSA-N
}}

'''Methoxmetamine''' (also known as '''3-MeO-2'-Oxo-PCM''', '''MXM''' and '''MMXE''') is a [[dissociative drug|dissociative]] [[anesthesia|anesthetic]] of the [[arylcyclohexylamine]] class that is closely related to [[methoxetamine]] and has been sold online as a [[designer drug]].<ref name="Mitsumoto_2015">{{cite journal | url=https://link.springer.com/article/10.1007/s11419-015-0293-6 | title=Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market |author1=Asuka Kaizaki-Mitsumoto |author2=Naoki Noguchi |author3=Saki Yamaguchi |author4=Yuki Odanaka |author5=Satoko Matsubayashi |author6=Hiroki Kumamoto |author7=Kiyoshi Fukuhara |author8=Masahiko Funada |author9=Kiyoshi Wada |author10=Satoshi Numazawa | journal=Forensic Toxicology | date=November 2015 | doi=10.1007/s11419-015-0293-6}}</ref>

==References==
{{Reflist}}


{{Hallucinogens}}
{{Glutamate receptor modulators}}
{{Sigma receptor modulators}}

[[Category:Designer drugs]]
[[Category:Dissociative drugs]]
[[Category:O-Methylated phenols]]


{{hallucinogen-stub}}